Hims & Hers’ 458% Rally Tested as FDA Undercuts Obesity Sales
The telehealth company’s meteoric rise has hit a roadblock after FDA regulations challenge its weight-loss drug business, setting up a crucial test for the stock ahead of Monday’s earnings report.
The telehealth company’s meteoric rise has hit a roadblock after FDA regulations challenge its weight-loss drug business, setting up a crucial test for the stock ahead of Monday’s earnings report.
